Imaging Biomarkers in Parkinson s Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01496599|
Recruitment Status : Completed
First Posted : December 21, 2011
Last Update Posted : March 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- Parkinson s disease (PD) causes slow movement, stiffness, and tremor. It results from the loss of a brain chemical called dopamine. PD gets worse over time, but researchers do not fully understand why the brain cells that produce dopamine stop working or die in people with PD. This study will use different ways of imaging the brain and brain chemicals to look at PD. It will compare brain imaging in people who definitely have PD to people who might have PD and to people without signs of PD. It will provide more information how the brain in people with PD changes over time.
- To understand the changes that occur in the brains of people with Parkinson s disease.
- Individuals at least 18 years of age who have definite or possible Parkinson s disease.
- Healthy volunteers at least 18 years of age.
- Participants will have a screening visit with a physical exam and medical history.
- Participants will visit the National Institutes of Health Clinical Center every 18 month or 3 years for up to 9 years. There will be up to 6 total visits. Most visits will last 5 to 6 hours a day for 1 to 3 days.
Some or all of the following tests will be performed at each visit:
- Magnetic resonance imaging to take pictures of the brain. Some of these tests will be done at rest. Others will require participants to perform an activity during the scan.
- Medication withdrawal for 12 hours overnight for people taking PD medications. This may be done before some scans. Participants who feel unwell when they stop taking medications will be allowed to start taking them again.
- Participants will continue with the follow up visits until the end of the study.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||62 participants|
|Official Title:||Imaging Biomarkers in Parkinson Disease|
|Actual Study Start Date :||January 24, 2012|
Subjects without PD diagnosis
Parkinsons Disease subjects
Subjects fitting the MSD Clinical Diagnostic Criteria for PD
Prodromal Parkinson disease
Subjects fitting the MDS prodromal criteria for PD
- Using MRI, we will measure signal intensities of iron-rich structures using T2 sequences and calculate phase shift values in these structures with susceptibility weighted sequences. We will also measure clinical symptom severity with the UPDRS s... [ Time Frame: 10 years ]-Structural MRI (SWI images): The primary outcome measure is the difference in susceptibility changes in iron-rich structures (ie. The SN, red nucleus, striatum) across groups and within groups over time.-Clinical presentation: We will evaluate how the prodromal symptoms influence the progression to clinical PD.
- Structural MR (morphometry and diffusion analyses) [ Time Frame: 10 years ]The outcome measures are the differences in gray and white matter morphometry across groups and within groups over time. We will derive measures such as fractional anisotropy, trace, and parenchymal volume fractions as measures of fiber tract integrity, across groups and within groups over time.
- fMRI [ Time Frame: 10 years ]The outcome measure for fMRI is the difference in resting state functional connectivity patterns as reflected by BOLD signal fluctuations and their dynamics across groups and over time.
- MRS [ Time Frame: 10 years ]The outcome measure for MRS is the difference in the spectroscopy signal amplitude of phosphorus-containing compounds and neurotransmitters in the sensorimotor cortices and basal ganglia across groups and over time.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 100 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- INCLUSION CRITERIA:
For all subjects:
- Age 18 or older.
- Subjects must fulfill either the clinically defined PD, prodromal PD or not having any of the red flags following the MDS criteria for PD.
- Able to give informed consent or, if there is evidence of cognitive decline, able to appoint a durable power of attorney (DPA) who can give informed consent.
- More than 7 alcoholic drinks a week for females or 14 alcoholic drinks a week for males.
- History of a neurologic disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, a movement disorder other than the ones under study, epilepsy or a history of seizures or any abnormal or focal finding on neurological exam other than that associated with those studied in this protocol.
- History of any head injury with loss of consciousness
- Pregnancy or positive pregnancy test before the research procedure due to the risks associated with MRI scans. This would exclude subjects from participating in the protocol at that time.
- Inability to lie flat on the back for up to 2 hours
- Claustrophobia or a feeling of discomfort from being in small, enclosed spaces.
- Surgically or traumatically implanted metallic foreign bodies, such as pacemakers, implanted medical pumps, implanted hearing aids, metal plates in the skull or metal implants in the skull or eyes (other than dental fillings) that may be physically hazardous during an MRI, or might distort the images.
- Ablative surgery or implanted electrodes and generator for deep brain stimulation
- Use of the following therapies which may affect mitochondrial function: Coenzyme Q10, vitamin E, vitamin C, anti-retroviral drugs, chemotherapeutic agents, anti-epileptics agents or antibiotics. (Use ofthese substances will prevent getting MRS scan only).
- Have uncontrolled head movements that may impair image data collection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01496599
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Silvina G Horovitz, Ph.D.||National Institute of Neurological Disorders and Stroke (NINDS)|
|Responsible Party:||National Institute of Neurological Disorders and Stroke (NINDS)|
|Other Study ID Numbers:||
|First Posted:||December 21, 2011 Key Record Dates|
|Last Update Posted:||March 21, 2023|
|Last Verified:||March 13, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.We will share IPD and data dictionaries that underlie results in a publication. The data sharing will be restricted to those subjects whom have agreed to data sharing, and those authorized by the IRB if re-consenting were not an option.|
Clinical Study Report (CSR)
|Time Frame:||Starting 1 year after publication.|
|Access Criteria:||IPD will be shared with qualified investigators, if allowed by IRB@@@@@@Any request for data sharing will be first reviewed by the protocol PI. @@@@@@The request must include the proposed use of the data. When requested data has IRB approval for data sharing, and the PI considers it a reasonable request, a memo of understanding will be signed by the parts, including the allowed use for the data. This will be done in consultation with the office of Tech Transfer.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases